RxDoctor Payments Data

Daniel Hayes

Medical Oncology · Ann Arbor, MINPI 1124184965

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,710 of the $26,545 with a category attached, or 85.6%. Cepheid accounts for 99.5% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $10,318 and has fallen 59.0% since, to $4,230 in 2024.

$26,545in general payments, 2019–2025

Across 17 payments — averaging $1561.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cepheid$26K
  • Menarini Silicon Biosystems, Inc.$131
$1,713,009in research payments, 2019–2025

Across 80 payments — averaging $21,413 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Menarini Silicon Biosystems, Inc.$1.2M
  • Cepheid$474K
  • Macrogenics, Inc.$5K
  • Merck$492

What the payments were for

  • Consulting fees$22,71086%
  • Travel & lodging$3,46413%
  • Food & beverage$3711%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cepheid15$26,414
Menarini Silicon Biosystems, Inc.2$131

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,545 in reported general payments places this provider in the 80th percentile of 170 medical oncology providers in Michigan.

See all medical oncology providers in Michigan →

Other medical oncology in Ann Arbor

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →